Stopping finasteride for chemo Finasteride/Dutasteride 3/12/2025
A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity CRISPR Is Curing People Right Now. Genetic Hair Loss is Next?
CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.
community Someone here experience with/or knows stories of cancer-patience regrowing hair?
Hair regrowth after chemotherapy varies; some experience thinner or differently colored hair, while others may see fuller regrowth. Treatments like essential oils, vitamins, and lifestyle changes are discussed, but no specific medications like Minoxidil or Finasteride were used by the original poster.
community There’s a war against finasteride and dht blockers
Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.
community Dutasteride thrice weekly beats finasteride. But daily?
Dutasteride taken three times a week is more effective for hair regrowth than daily finasteride, with fewer side effects. Some users combine dutasteride and finasteride for better results, while others prefer dutasteride alone due to its longer half-life and potential fertility concerns.
community Finasteride saved my hair and made it curly/wavy
Finasteride improved hair density and changed hair texture from wavy to curly for the user. The user took 1mg of oral finasteride daily without using minoxidil.
Related Research
6 / 6 results
research Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.
research Safety concerns when using novel medications to treat alopecia
This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.
research Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.
research Pharmacological Treatment of Alopecia
This chapter reviews current and emerging pharmacological treatments for alopecia, noting that the FDA's classification of alopecia as a cosmetic disease has limited drug development and led to off-label use of potentially dangerous compounds.
research Medical Treatment of Alopecia
This article reviews various treatments for alopecia, highlighting that minoxidil, finasteride, PRP therapy, and hair transplants are the most commonly used options, but it reports no new clinical results.
research Beard Alopecia: An Updated and Comprehensive Review of Etiologies, Presentation and Treatment
This review provides a detailed overview of the causes, prevalence, pathophysiology, clinical presentation, and treatment of beard alopecia, highlighting conditions such as alopecia areata, pseudofolliculitis barbae, and tinea barbae, and aims to serve as a resource for clinicians handling such cases.